Somatropin Market Analysis

Somatropin is a recombinant human growth hormone indicated for the treatment of growth hormone deficiency in children and adults, as well as Turner syndrome, Prader-Willi syndrome, Chronic Renal Insufficiency (chronic kidney disorder), and others. Somatropin stimulates linear growth (height), tissue growth, and lipid, protein, carbohydrate, and mineral metabolism. Injections of somatropin are used to treat growth hormone insufficiency in both adults and children. Growth hormone is a natural hormone produced by the body. Children with specific diseases  such as Growth hormone deficiency (GHD),that hinder normal growth and development can potentially benefit from somatropin injections to accelerate their growth. In addition to being available as a powder in vials and cartridges to be combined with liquid and administered subcutaneously, somatropin injection is also available as a solution (liquid) in prefilled dosing pens and cartridges (under the skin). Adults often receive a somatropin injection once a day to replenish growth hormone. In individuals with human immunodeficiency virus (HIV) who have HIV-associated wasting syndrome, somatropin injection (Serostim) is used to enhance body weight and physical endurance. Injections of somatropin (Zorbtive) are used to treat growth hormone deficiency.

Global Somatropin Market is estimated to be valued at US$ 3.6 Bn in 2022 and is expected to exhibit a CAGR of 7.2% over the forecast period (2022-2030).

Figure 1: Global Somatropin Market Share (%) Analysis, By Dosage Form, 2022

Global Somatropin Market – Drivers

Product approval from regulatory authorities such as ANVISA (National Sanitary Surveillance Agency), for drugs of Somatropin is expected to drive growth of the global somatropin market over the forecast period.

Product approval from regulatory authorities such as ANVISA (National Sanitary Surveillance Agency), for drugs of Somatropin is expected to drive growth of the global somatropin market over the forecast period. For instance, in May 2019, ANVISA (National Sanitary Surveillance Agency), approved the biosimilars named Criscy (Somatropin), which is safe and effective in the treatment of patients with pathologies associated with growth hormone deficiency. Criscy (Somatropin) is manufactured by Cristalia, a pharmaceutical & biotechnological research and development company, which is headquartered in Sao Paulo, Brazil.

Increasing long term effect of growth hormone therapy on children with growth hormone deficiency is expected to drive the global somatropin market growth over the forecast period.

Increasing long term effect of growth hormone therapy on children with growth hormone deficiency is expected to drive the global somatropin market growth over the forecast period. For instance, according to the data published in the Journal Acta Biomedica, in 2020, a study was conducted among 252 short children with growth hormone deficiency, 63 with idiopathic short stature, 26 with small for gestational age, and 9 with Turner syndrome who were treated in King Abdullah International Medical Research Center, Jeddah, Saudi Arabia with growth hormone in 2018.

Somatropin Market  Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 3.6 Bn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	7.2 %	2030 Value Projection:	US$ 6.3 Bn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Dosage Form: Powder, Solvent By Application: Grwth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age, SHOX Deficiency, Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, AnkeBio Co. Ltd., Reliance Life Sciences, GeneScience Pharmaceuticals, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., JCR Pharmaceuticals Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., and USV Limited
Growth Drivers:	Product approval from regulatory authorities Increasing long term effect of growth hormone therapy on children with growth hormone deficiency
Restraints & Challenges:	Increasing presence of alternative drugs for growth hormone deficiency

Global Somatropin Market- Impact of the Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.

The COVID-19 pandemic has affected clinical trials drastically. For instance, on April 23, 2020, according to a survey conducted by Medidata Solutions, Inc., a company which markets and develops software as a service for clinical trials, conducted a survey which showed observations such as 63% of survey respondents reported that they had stopped recruiting new patients for ongoing clinical trials and 43% of the respondents had postponed their studies.

Moreover, since the COVID-19 virus outbreak in December 2019, the supply chain of growth hormone deficiency drugs was hampered and the somatropin market was affected in a negative way, however the market recovery was seen over the late phase of COVID-19.

Global Somatropin Market– Restraints

Increasing presence of alternative drugs for growth hormone deficiency is expected to hamper growth of the Global Somatropin Market over the forecast period.

For instance, according to the data published in the biostation which provides information about scientific data where in 2022, Sermorelin therapy is less expensive than human growth hormone treatment, sometimes by as much as 10%. Injection or a multi-dose auto pen are two alternatives for administration of drug.

Global Somatropin Market– Regional Analysis

On the basis of region, the Global Somatropin Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, Europe market is expected to witness significant growth, owing to key companies in market focusing on research and development activities for drug development for treatment indicated for Pediatric Growth Hormone Deficiency. For instance, on June 12, 2022, Novo Nordisk A/S, a global healthcare company headqutered in Denmark announced results of once-weekly Sogroya (somapacitan) injection in helping children achieve growth targets of annualized height velocity (AHV).1 The phase 3 results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented at the Endocrine Society’s Annual Meeting (ENDO 2022) in Atlanta, Georgia (U.S.).

Figure 2: Global Somatropin Market Value (US$ Bn), by Region, 2022

Global Somatropin Market– Key Players

Major players operating in the Global Somatropin Market include Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, AnkeBio Co. Ltd., Reliance Life Sciences, GeneScience Pharmaceuticals, Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., JCR Pharmaceuticals Co., Ltd., Sandoz International GmbH, Ipsen Pharma, LG Chem, Merck KGaA, Genentech, Inc., Ferring B.V., and USV Limited.